The absolute lymphocyte/monocyte ratio recovery during ABVD treatment cycles is not significantly impacted by the use of myeloid growth factors and predicts clinical outcomes in classical Hodgkin lymphoma regardless of their use

The absolute lymphocyte/monocyte ratio recovery during ABVD treatment cycles is not significantly impacted by the use of myeloid growth factors and predicts clinical outcomes in classical Hodgkin lymphoma regardless of their use

Gregory P Kaufman,1 Kay M Ristow,1,2 Svetomir N Markovic,1,2 Luis F Porrata1,2 1Department of Internal Medicine, 2Division of Hematology, Mayo Clinic, Rochester, MN, USA Abstract: Risk stratification of patients with classical Hodgkin lymphoma (cHL) remains suboptimal. The ratio of the absolute ly...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Kaufman GP, Ristow KM, Markovic SN, Porrata LF
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2014
Materias:
Diseases of the blood and blood-forming organs
RC633-647.5
Acceso en línea:https://doaj.org/article/7fd25cc8e5eb42a7bd9fa81a4f9a54ee
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Ejemplares similares